Benzothiazoles as potential antiviral agents

Yahya I. Asiri, Abdulrhman Alsayari, Abdullatif B. Muhsina, Yahia N. Mabkhot and Mohd. Z. Hassan

Keywords
antiviral; benzothiazole; COVID-19; dengue; HIV

Correspondence
Dr. Mohd. Z. Hassan, Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha 61441, Saudi Arabia.
E-mails: zaheen@kku.edu.sa; drzahin@gmail.com

Received March 24, 2020
Accepted June 13, 2020
doi: 10.1111/jphp.13331

Abstract

Objectives The recent viral pandemic poses a unique challenge for healthcare providers. Despite the remarkable progress, the number of novel antiviral agents in the pipeline is woefully inadequate against the evolving virulence and drug resistance of current viruses. This highlights the urgent need for new and improved vaccines, diagnostics and therapeutic agents to obviate the viral pandemic.

Key findings Benzothiazole plays a pivotal role in the design and development of antiviral drugs. This is evident from the fact that it comprises many clinically useful agents. The current review is aimed to provide an insight into the recent development of benzothiazole-based antiviral agents, with a special focus on their structure-activity relationships and lead optimisation. One hundred and five articles were initially identified, and from these studies, 64 potential novel lead molecules and main findings were highlighted in this review.

Summary We hope this review will provide a logical perspective on the importance of improving the future designs of novel broad-spectrum benzothiazole-based antiviral agents to be used against emerging viral diseases.

Introduction

The current global scenario indicates that new microbial threats will continue to emerge at an accelerating pace, mainly due to globalisation and unprecedented climate change. As compared to the only 260 known human pathogenic viruses, the unknown varieties of viruses represent 99.9% of potential zoonoses, which cannot be diagnosed until symptoms are noticed. Moreover, the recent unusual worldwide outbreaks of Nigerian Lassa virus in 2018, Indian Nipah virus in 2018, Brazilian yellow fever in 2017, West African Ebola in 2017, Brazilian Zika virus in 2015 and worldwide coronavirus disease 2019 (COVID-19) took terrible tolls, both on human life and on the global economy.

Viruses are obligate intracellular pathogens consisting of a DNA or RNA genome enclosed within a proteinaceous capsid. Due to its rapid replications, mutations and adaptions in host cells, the treatment of viral infections with vaccines or small molecules is an arduous task facing healthcare providers. However, due to the advent of newer techniques such as virome, robust cell culture, cytopathic effect, immunofluorescence, high-throughput screening (HTS) and other drug discovery tools, antiviral chemotherapy has witnessed a revolution in controlling HIV-1, HBV, HCV and herpes viruses (HSV and CMV). In the last three decades approximately 88 new antiviral drugs have been approved by the US Food and Drug Administration (FDA), which includes a diverse array of small molecules, interferons, monoclonal antibodies, peptides and oligonucleotides. All these drugs are either acting as host targeting agents such as immunomodulating agents, toll-like receptor (TLR) agonists, human inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors, C-C chemokine receptor type 5 (CCR5) modulators or viral targeting agents such as polymerase, protease, integrase, non-structural protein 5A (NS5A) and neuraminidase inhibitor. Gene therapies are also now popular in the field of medicine, and they define a new-age viral treatment where genes are delivered into infected cells to interfere with viral replications. Despite this remarkable progress, the number of novel antiviral agents in the
pipeline is woefully inadequate against the evolving virulence and drug resistance of current viruses.\[21\] This highlights the urgent need for new and improved vaccines, diagnostics and therapeutic agents to obviate the viral pan-demic. The antiviral potential of benzothiazole derivatives has recently gained momentum due to its robust in-silico virtual and HTS, which result in higher hit-to-lead discoveries (Figure 1).\[22\] To date, a fair number of related articles have been published but not a single review on this topic has been reported. Thus, there appears to be a real need for a review article summarising the benzothiazolyl antiviral agents. This mini-review makes no attempt to be comprehensive but highlights the potential of benzothiazole analogues against various viral diseases with a focus on structure–activity relationships (SAR), as well as their molecular targets. This review will surely help in generating significant multiple pharmacophore hypotheses and draw novel insights which contribute to the development of benzothiazole-based antiviral agents.

**Anti-dengue agents**

Dengue is a mosquito-borne haemorrhagic fever caused by a single positive-stranded RNA virus of family *Flaviviridae*. According to WHO, an estimated 50 million dengue infections occur every year which accounts for thousands of deaths from dengue haemorrhagic dengue (DHF) and dengue shock syndrome (DSS). Dengue genotypes, viz. DEN1, DEN2, DEN3 and DEN4, are very closely related serotypes; thus their cross-reactive antibodies aggravate the risk of severe dengue shock in people experiencing repeated dengue virus (DENV) infections.\[23,24\] Currently, no effective treatments are available for dengue. Most investigational new anti-dengue agents directly target the viral structural proteins (capsid \([C]\), prM and E) or nonstructural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) by cellular proteases and viral serine protease, composed of NS2B and NS3.\[25\]

**DENV NS2B/NS3 protease inhibitors**

The NS2B/NS3 protease (PR) represents an important molecular target for anti-dengue drug design. Currently, no clinically available PR inhibitors (PIs) exist for the treat-ment of dengue. Recently, a novel compound library of hybrid benzothiazole-quinoline derivatives was developed as PIs by Lai *et al*. This hybrid pharmacophore demonstrated interesting anti-dengue activity and became a potential lead in the further development of various hybrid PIs. One of the potent compounds identified was compound 1, which was found to be a competitive inhibitor of DENV2 NS2B/NS3 PR with an IC\(_{50}\) value of 0.91 ± 0.05 \(\mu\)M (\(K_I\) 2.36 ± 0.13 \(\mu\)M).\[26\] Furthermore, a group of scientists led by Lai *et al*. performed HTS research of 250 compounds with the aim of developing nonpeptidic PIs. They identified benzothiazole containing naphthalenoxysbenzamide as a potential candidate for a novel anti-dengue drug targeting DENV PR. Initially, a thiolene derivative (2) was discovered to inhibit the DENV-2 PR which was optimised by replacing it with the benzothiazole ring system (3), and the thioether linkage was bioisosterically replaced by an ether function (Figure 2).\[27\].

**DENV helicase inhibitors**

RNA helicase is a common key enzyme in various viruses, such as HIV, HCV, influenza A and swine fever viruses. This enzyme unwinds both DNA and RNA, as well as affecting many DNA and RNA metabolic processes. Thus, RNA helicase represents a key target for new therapeutics against the aforementioned viruses.\[28\] Moreover, drugs targeting one viral variant could be useful for treating another virus. Keeping this in mind, Sweeney *et al*. evaluated potential anti-HCV agents against the DENV using robust DENV NS3 ATPase assay and DENV helicase-catalysed RNA unwinding assays. Surprisingly, NIH molecular probe ML283, a previously reported benzothiazole oligomer (14) derived from the dye primuline (12), emerged as a novel lead template inhibiting DENV NS3 with an IC\(_{50}\) value of 500 nM and DENV RNA helicase with an IC\(_{50}\) value of 3.5 \(\mu\)M.\[29\] Encouraged by the persuasive results of this benzothiazolyl oligomer, a ligand-based pharmacophore model was also generated to screen 1 201 474...
Figure 2 Benzothiazole as DENV NS2B/NS3 PIs. [Colour figure can be viewed at wileyonlinelibrary.com]

Figure 3 Development of DENV helicase inhibitors by pharmacopore-based ligand search. [Colour figure can be viewed at wileyonlinelibrary.com]
Compounds of the ZINC Database. Filtered compounds were then docked at the active site of NS3 helicase which yielded five potential benzothiazole hits (4–8) with satisfactory ADMET properties. However, the results of in silico studies are yet to be validated in a wet lab (Figure 3).[30]

**DENV RNA dependent RNA polymerase (RdRp) inhibitors**

The RdRp is responsible for viral replication and represents a selective flavivirus molecular target as its homologue is absent in humans. Recently, several new chemotypes targeting DENV RdRp have been discovered by re-evaluating the previously reported compounds that are effective against the HCV NS5B RdRp. In this context, Tarantino et al. reported the biochemical and crystallographic characterisation of a pyridobenzothiazole lead (9) as an inhibitor of flavivirus RdRp in micromolar range possessing very high selectivity against DENV2.[31] Subsequently, optimisation of a pyridobenzothiazole scaffold by a substituted phenyl ring provided a broad-spectrum antiviral agent 10 (Figure 4).[32]

**Anti-hepatitis C virus**

Hepatitis C virus (HCV) infection is a major global health concern. It is known as the chief cause of liver failure that often leads to hepatocellular carcinoma. Globally, approximately 150 million people are living with HCV infections.[33] HCV is a single-stranded RNA virus of the Flaviviridae family with seven major genotypes (HCV1-7).[34] High-throughput antiviral drug discovery screens have been extensively performed to identify inhibitors of viral protease (serine protease for HCV) and inhibitors of the RNA-dependent RNA polymerase (RNA replicase).[35] Vaccines for preventing hepatitis A and B are now clinically available. Although available directly acting antiviral agents have been successful in managing HCV, emerging resistance, unfavourable pharmacokinetic properties and high treatment costs continue to present challenges.[36] Thus, there is a pressing demand to discover novel anti-HCV therapeutic agents. A significant number of benzothiazole analogues have demonstrated promising anti-HCV activity, as noted in the following.

**HCV NS3 helicase inhibitors**

Replication of HCV in human cells requires the action of the HCV non-structural protein 3 (NS3), which exhibits both protease and helicase activities. The HCV polyprotein is comprised of 3000 amino acids that can be divided into a structural region (C-p7 proteins) and a non-structural (NS) region (NS2–NS5B proteins). Only the NS3–NS5B region of the polyprotein is required for genome replication in cell cultures. Thus, HCV NS3 is an imperative drug target due to its main role in viral replication.[37,38]

Using the HTS of 827 compounds in the National Cancer Institute (NCI, US) mechanistic set, Li et al. discovered commercial dyes thioflavin S (11) and primuline (12) as the most potent inhibitors of NS3 catalysed DNA and RNA unwinding at the micromolar range. Further resolutions into their pure components resulted in potent benzothiazole tetramer (13). Subsequent insight into the contribution of the carboxamide group (14) as a more specific agent helped to obtain a potent helicase inhibitor with an IC₅₀ value of 2.6 ± 1 µM (Figure 5).[39]
HCV NS5B polymerase inhibitors

HCV NS5B polymerase is an attractive target for HCV therapeutic intervention as it is responsible for the replication of positive-strand genomic RNA. HCV NS5B polymerase selectively utilises the viral RNA template which the host mammalian cells are lacking. Manfroni et al. reported novel pyridobenzothiazole derivatives (15) as HCV NS5B polymerase inhibitors through scaffold hopping strategy. These compounds were shown to have interesting polymerase inhibitory activity. However, in-vitro studies failed to predict its anti-HCV activity due to poor permeability. Detailed biochemical studies confirmed the allosteric modulation of pyridobenzothiazoles through non-competitive inhibitions of the ribonucleotide substrate and competitive inhibitions of the RNA template (Figure 6).

In the pursuit of identifying novel small molecule inhibitors of hepatitis C virus replication, scientists at the Merck Research laboratory, USA, identified a new library of carbanucleoside derivatives (16) as lead molecules. SAR studies were conducted around the pyrimidine core to improve the potency and pharmacokinetic profile of these inhibitors. A benzothiazole moiety was found to be the optimal substituent at the pyrimidine 5-position (compounds 17 and 18). The 4-methyl derivative emerged with enhanced rat in vivo profile demonstrating a very good
replicon potency, selectivity and rodent plasma/target organ concentration.\textsuperscript{[43]} Further, introduction of a nitrogen atom into the benzene ring of a previously identified HCV replication (replicase) benzothiazole inhibitor, resulted in the discovery of more potent pyridothiazole analogues (19) (Figure 7).\textsuperscript{[44]}

HCV replicon inhibitors

HCV replication in cell lines was practically impossible before the development of subgenomic replicons which replicate freely in the human hepatoma cell line Huh-7. Significant progress has been achieved with regard to the replicon system, allowing for the validated protocols of replication assays for HCV genotypes 1a, 1b, and 2a. The HCV replicon system has opened new venues for detailed molecular studies of RNA replication and HCV-host interactions as well as for the discovery of novel inhibitors of HCV replication.\textsuperscript{[45]} Considering the uses of the HCV replicon assay, researchers at Second Military Medical University, China performed a cell-based anti-HCV screen of an intramural compound against the HCV genotype 2a variant. Their finding demonstrated that benzothiazolamide derivative (20) possesses significant HCV inhibitory activity (IC$_{50}$ = 26.81 µM) with little cytotoxicity (CC$_{50}$ = 155 µM). The compound was found to be effective against other genotypes such as the 1b HCV replicon (IC$_{50}$ = 9.3 µM). Further optimisation has resulted in a disulphona-mide analogue of benzothiazole (21) as potent anti-HCV agent with good selectivity towards the target NS5A.\textsuperscript{[46]}

Similarly, another scientist, Montalvao et al., similarly

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure6.png}
\caption{Pyridobenzothiazoles as NSSB polymerase inhibitors. [Colour figure can be viewed at wileyonlinelibrary.com]}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure7.png}
\caption{Benzothiazolyl-carbanucleoside as NSSB polymerase inhibitors. [Colour figure can be viewed at wileyonlinelibrary.com]}
\end{figure}
reported some benzothiazole carboxamide derivatives as HCV replicon inhibitors. Indole containing benzothiazole derivative (22) demonstrated 70% suppression of the HCV replicon and 35% cytotoxicity against the host cells (Figure 8).\cite{47}

3.4 Miscellaneous anti-HCV agents

Some of the reported anti-HCV agents do not have any selectivity against the specific molecular targets and act through multiple or unknown mechanisms. Neyts et al. reported the benzothiazolyl-coumarin conjugated compounds linked through -SCH$_2$- as potential antiviral agents inhibiting HCV replications. A methoxy-substituted coumarin analogue (23) exhibited low micromolar EC$_{50}$ at 29 µM against HCV.\cite{48} Peng et al. also demonstrated the significant inhibitory anti-HCV activity of 2-(4-nitroanilino)-6-methylbenzothiazole (24). The benzothiazole derivative 24 was found to inhibit HCV RNA-dependent RNA polymerase (RdRp) and HCV RNA replication in a dose-dependent manner (EC$_{50}$ 8 ± 0.5 µM), consistent with a non-competitive model of inhibition (kinetic constant $K_i$ 7.76 µM) (Figure 9).\cite{49}

**Anti-herpes agents**

Herpes simplex virus (HSV) 1 (cold sores, fever and blisters) and 2 (genital herpes) are highly contagious human viruses of the Herpesviridae family. Many of the common antiviral drugs are in clinical use for the treatment of HSV, e.g. idoxuridine, trifluridine, acyclovir, famciclovir and foscarnet. Nevertheless, research is still ongoing in the development of newer agents with enhanced activity.\cite{50} El-Sherbeny et al. evaluated some pyrimido[2,1-b]benzothiazole and benzothiazolo[2,3-b]quinazoline derivatives for anti-HSV activity. These compounds showed potential antiviral effects against HSV1 with a 50–61% reduction in the viral plaques.\cite{51} Abdel-Aziza et al. also synthesised...
some benzothiazolyl-arylhydrazones. Evaluation against HSV1 revealed that piperidinyl amidrazones (25) possessed significant antiviral activity (Figure 10).[52]

A non-toxic benzothiazolyl urea drug, frentizole (26) which was approved by the FDA for the treatment of rheumatoid arthritis and systemic lupus erythematosus has been studied for the immunosuppressive and superimmunosuppressive dose levels on the resistance of the mice to viral infections. The mean survival time of specific pathogen-free male mice pre-treated with frentizole or azathioprine at 100, 50 or 25 mg/kg and infected with herpes simplex and influenza virus was reduced.[53]

**Anti-HIV agents**

Acquired immunodeficiency syndrome (AIDS) is mainly caused by human immunodeficiency virus type 1 (HIV-1) and continues to be a major contributor to the global burden of disease as it has claimed more than 32 million lives so far.[54] Recently, outstanding progress in the discovery of novel anti-HIV agents has led to implementing better therapeutic regimes for this devastating virus.[55] The development of a combination antiretroviral therapy has completely transformed HIV from a progressive illness with a fatal outcome into a chronic manageable disease.[56] The majority of the currently utilised anti-HIV drugs exert their effects through validated HIV molecular targets which include transcriptase, integrase and protease enzymes.[57] Hence, developing potential anti-HIV agents targeting these enzymes remains a main research interest. Towards this end, numerous benzothiazolyl derivatives have been reported to exhibit potent anti-HIV activity both in vitro and in vivo; however, the clinical efficacy of benzothiazole has not yet been demonstrated.

**Reverse transcriptase inhibitors**

HIV-1 reverse transcriptase (RT) is one of the vital targets of retroviruses. It catalyses the conversion of HIV-RNA into a double-stranded DNA which then integrates into the human genome.[58] In recent years, there has been increasing evidence of the importance of non-nucleoside RT inhibitors (NNRTIs) for HIV therapeutic intervention. Encouraged by this response, Akbay et al. synthesised some benzothiazole derivatives as potential RT inhibitors determined through the scintillation proximity assay using bromodeoxyuridine (BrdUMP). Its antiviral potency was indicated by the in vitro binding inhibition of thymidine with the RT enzyme. Compound 2-(p-chlorophenoxy)methylbenzothiazole (27) was found to be more active than the other compounds, having an IC50 value of 0.34 µmol/l (Figure 2).[59] More recently, Cheung et al. also performed a screening of a library of 256-compounds to identify a structural “mimic” of a lead fused tetracyclic indole derivative (28).[60] Diheteroarylamide-type compounds, containing a common 5-nitroisobenzothiazole derivative (29), emerged as potent anti-HIV agent. This compound was evaluated against the isolate (E00443), which greatly reduced susceptibility to NNRTI’s and remained active, with an EC50 of 1.3 µM (Figure 11).[61]

**Protease inhibitors**

HIV-1 protease (HP) is essential for the life-cycle of HIV and the maturation of infective HIV virion by catalysing the hydrolysis of Gag and Gag-pol polyproteins resulting in the production of structural proteins, such as viral envelope glycoproteins and the enzymes reverse transcriptase, integrase, and protease.[62] Thus, it is an important target for HIV treatments. Research efforts aimed at developing a protease inhibitor (PI) led to the approval of many PI drugs in the mid-90s which are now being used in combination with RTIs in highly active antiretroviral therapy (HAART).[63] Previously, the structure-based drug design (SBDD) and X-ray crystallographic analysis of HP has resulted in exciting peptide-based PIs as preclinical drug candidates, however, the majority of them failed in clinical trials due to their poor physicochemical properties. This
inspired the development of several PIs containing non-peptidic fragments with superior biopharmaceutical properties. In pursuit of this goal, the research laboratory of Prof. A. K. Ghosh in collaboration with Tibotec Inc., Belgium, also extensively studied on the SBDD strategies based upon promoting extensive interactions in the active site of HP, particularly with the backbone atoms. They were the pioneers in discovering a range of exceptionally potent non-peptide HIV-1 PIs, of which one drug darunavir (DRV) (IC₅₀ 3.8 nM), was approved in 2006 by the US FDA for the treatment of drug-resistant HIV. DRV, a 3(R),3a(S),6a(R)-bis-tetrahydrofuranyl-urethane (bis-THF) analogue is now utilised as a frontline therapy for HIV/AIDS. Based on the protein crystallography of darunavir bound to HP, they proposed a pharmacophore model for PI effective against drug-resistant HIV. The model suggests that the hydrophobic, electrostatic and critical hydrogen bonding with the backbone atoms located in the S2 to S2'-subsites of protease is essential. The transition hydroxyl group binds to a catalytic aspartate, while a P1 and P1' ligand occupy the S1 and S1' subites (Figure 12).[^65] To further optimise the bis-THF structural template, they introduced an unprecedented 6-5-5 ring-fused crown-like tetrahydroxyanofuran as the P2 ligand and an aminobenzothiazole as the P2' ligand with the (R)-hydroxyethylsulfonamide isostere. The resultant analogue 31 emerged as a potent PI against drug-resistant viruses with several fold higher potency (IC₅₀ 0.39 nM) than the drug DRV (Ghosh et al.,[^66]). Further modification was carried out by introducing a 6-5-5 ring-fused octahydrocyclopentylpyranofuran as the P2 ligand and difluorophenylmethyl as the P1 ligand. The resulting analogue 32 showed excellent enzyme inhibitory potency (IC₅₀ 27 pM) with a strong antiviral activity against a panel of highly multidrug-resistant HIV 1 variants.[^67] Extensive lead optimisation at the P2' region was aimed at improving the broad-spectrum activity as well as the overall ADME profile of these derivatives.

Surleraux, et al., 2005, at Tibotec BVBA, Belgium, did parallel research exploring the P2' region to identify new classes of broad-spectrum PIs with improved pharmacokinetic properties. They developed an aminobenzothiazolyl analogue (33) of DRV with pronounced broad-spectrum activity. Although DRV has a high genetic barrier to the development of HIV-1 resistance, many DRV-resistant strains have recently been reported.[^69] Keeping these in mind Takamatsu et al. delved more into the development of PI-resistant antiviral drugs. They reported a new series of compounds produced by introducing P2-amino-substituted-bis-tetrahydrofuranylurethane (bis-THF) (34). The bis-THF derivative compounds emerged as potent agents inhibiting the replication of wild-type HIV-1 (EC₅₀

---

[^64]: In pursuit of this goal, the research laboratory of Prof. A. K. Ghosh in collaboration with Tibotec Inc., Belgium, also extensively studied on the SBDD strategies based upon promoting extensive interactions in the active site of HP, particularly with the backbone atoms. They were the pioneers in discovering a range of exceptionally potent non-peptide HIV-1 PIs, of which one drug darunavir (DRV) (IC₅₀ 3.8 nM), was approved in 2006 by the US FDA for the treatment of drug-resistant HIV. DRV, a 3(R),3a(S),6a(R)-bis-tetrahydrofuranyl-urethane (bis-THF) analogue is now utilised as a frontline therapy for HIV/AIDS. Based on the protein crystallography of darunavir bound to HP, they proposed a pharmacophore model for PI effective against drug-resistant HIV. The model suggests that the hydrophobic, electrostatic and critical hydrogen bonding with the backbone atoms located in the S2 to S2'-subsites of protease is essential. The transition hydroxyl group binds to a catalytic aspartate, while a P1 and P1' ligand occupy the S1 and S1' subites (Figure 12).[^65]

[^65]: To further optimise the bis-THF structural template, they introduced an unprecedented 6-5-5 ring-fused crown-like tetrahydroxyanofuran as the P2 ligand and an aminobenzothiazole as the P2' ligand with the (R)-hydroxyethylsulfonamide isostere. The resultant analogue 31 emerged as a potent PI against drug-resistant viruses with several fold higher potency (IC₅₀ 0.39 nM) than the drug DRV (Ghosh et al.,[^66]). Further modification was carried out by introducing a 6-5-5 ring-fused octahydrocyclopentylpyranofuran as the P2 ligand and difluorophenylmethyl as the P1 ligand. The resulting analogue 32 showed excellent enzyme inhibitory potency (IC₅₀ 27 pM) with a strong antiviral activity against a panel of highly multidrug-resistant HIV 1 variants.[^67] Extensive lead optimisation at the P2' region was aimed at improving the broad-spectrum activity as well as the overall ADME profile of these derivatives.

[^66]: Surleraux, et al., 2005, at Tibotec BVBA, Belgium, did parallel research exploring the P2' region to identify new classes of broad-spectrum PIs with improved pharmacokinetic properties. They developed an aminobenzothiazolyl analogue (33) of DRV with pronounced broad-spectrum activity. Although DRV has a high genetic barrier to the development of HIV-1 resistance, many DRV-resistant strains have recently been reported.[^69] Keeping these in mind Takamatsu et al. delved more into the development of PI-resistant antiviral drugs. They reported a new series of compounds produced by introducing P2-amino-substituted-bis-tetrahydrofuranylurethane (bis-THF) (34). The bis-THF derivative compounds emerged as potent agents inhibiting the replication of wild-type HIV-1 (EC₅₀.
0.22–10.4 nM) and multi-PI-resistant HIV-1 variant, including highly DRV-resistant HIVDRV/PSI. This compound had an EC50 ranging from 1.6 nM to 30.7 nM.[79] Ali and collaborators, at the University of Massachusetts Medical School, developed a series of novel PIs having phenyloxazolidinone P2 ligands (35). SAR studies showed that the introduction of polar substituents, such as methylsulfonyl group at the 3-position of the phenyl ring as P2 ligand significantly increased in vitro antiviral activity. A benzothiazole ring as P2 ligand was found to be optimal for enzymatic and antiviral activity against wild-type viruses and MDR viruses.[71] Another group of scientists at Janssen provided a new class of benzothiazole amide derivatives as novel pharmacokinetic enhancers of PIs inhibiting the CYP3A4 enzyme by replacing the sulphonamide with an amide linkage. The in vitro antiviral activity of amide derivatives against the wild type HIV-1 demonstrated that the replacement of sulphonamide group was not a good choice, as none of the compounds were active. However, an in vitro human liver microsomes (HLM)-based CYP3A4 inhibition assay showed a promising result. The amide analogue 36 demonstrated excellent ‘boosting’ properties when tested in dogs (Figure 13).[72]

In an effort to identify novel agents effective against the multidrug-resistant mutant HP, Ung, et al., 2014, performed a virtual screening of the Center of Chemical Genomics (CCG) library against the eye site pharmacophore model of HP. Further evaluation of the computational hits resulted into the identification of quinolinyl analogue (37) as a promising protease proteolytic agent. A subsequent ligand-based lead-hopping method yielded a novel potent 4-nitro-2-(2-thioxo-2,3-dihydrobenzo[d]isothiazol-6-yl)isocinodol-1,3-dione (38) as an allosteric modulator of HP proteolytic activity (Figure 14).[73]

**Integrase inhibitors**

The HIV-1 integrase (IN) enzyme is the retroviral enzyme that catalyses the insertion of the virally derived cDNA ends generated by the viral RNA genome through RT into host chromosomes. Since the approval of the IN inhibitor (INI) raltegravir, research on the development of INI has gained huge attention and several derivatives of different classes have been identified so far.[74,75] Towards this end, Gó et al. reported the discovery of a novel benzothiazolyl INI. In this study, a total of 80 000 natural compounds were virtually screened for their INI properties and subsequently tested for cell-based antiviral activities. Out of these, 3-(1,3-benzothiazol-2-yl)-8-[(bis[2-hydroxyethyl]amino)methyl]-7-hydroxy-2H-chromen-2-one (D719, 39) inhibited IN nuclear translocation in the immunofluorescence assay at 10 µM (Figure 15). The in-vitro anti-HIV activity of D719 revealed that p24 antigen production in HIV-1INB-infected human T cells was drastically reduced to half of its maximal effective concentration of 4.33 µM. Thus, D719 provides a novel lead and new insight into the molecular mechanism for future drug development of INI.[76]

**Miscellaneous anti-HIV agents**

Molecular hybridisation of bioactive pharmacophores has become a major contributor to the development of several synergistic biologically active molecules.[77] Based on this approach, different moieties have been clubbed with a benzothiazole derivative to optimise the antiviral potential of benzothiazole leads. Most of these hybrid benzothiazolyl analogues do not have any specific mechanism of HIV inhibitory activity but possess remarkable in-vitro anti-HIV potential (Figure 16). Based on these, Vicini et al. prepared two series of benzo[d]isothiazole (40) and benzothiazole (41) analogues containing Schiff bases and evaluated in-vitro against the HIV-1 (Retrovirus). The EC50 value of hybrid methyl derivative of benzo[d]isothiazole (40) was found to be >5 µM.[78] Bhavsar et al. reported the hybrid benzothiazolyl-coumarins as potential anti-HIV agents. The synthesised compounds were evaluated for their anti-HIV activity using the MTT method and showed potent antiviral activity against the wild type HIV-1 strain. Among these, a 6-chlorobenzothiazole derivative (42) showed a promising anti-HIV effect with an EC50 < 7 µg/mL. The SAR of these compounds showed that hydroxy substitution at the coumarinyl ring increased its activity, whereas bulky substitutions at the phenyl ring decreased the antiviral potency of these benzothiazole derivatives.[79] A series of benzothiazole-containing dioxothiazolines connected through an acetamide linkage (43) was also reported. While these compounds were not that much active against HIV-1 as compared to the reference drug, they provided an important lead for future development.[80] Heredia et al. screened some in-house antimicrobial compounds against the TZM-bl cells with the CCR5-dependent HIV-1 BaL strain in-vitro. A benzothiazolyl compound containing an indole moiety S660386 (44) emerged as the most potent antiretroviral agent, having potency in the nanomolar range. This hybrid derivative inhibits HIV-1 entry into cell lines, binds to the HIV-1 envelope protein and inhibits the interaction of GP120 to CD4. This compound had a unique and broad-range activity against primary HIV-1 isolates from different subtypes and geographical areas.[81] In 2011, Urano et al. discovered a benzothiazolyl-pyrimidine (BMMP, 45) small molecule as an inhibitor of the oligomerisation of HIV-1 Pr55Gag which is a key process in HIV-1 virion production.[82] The BMMP template was further optimised by linking with biotin, then evaluated against the presumed target, HIV-1 Pr55Gag or CA, by
Figure 13  Benzothiazole PIs discovered by Tibotec BVBA. [Colour figure can be viewed at wileyonlinelibrary.com]
means of surface plasmon resonance. The newly synthesised Biotin–BMMP hybrid (46) inhibited HIV-1 replication but showed no interaction with Pr55Gag or CA, suggesting that antiviral activity occurs through a different mechanism.\textsuperscript{[83]}

The 6-aminoquinolones have also emerged as a promising new class of HIV expression inhibitors, interfering with the Tat-mediated transactivation of the HIV-1 LTR promoter. On the basis of these recent findings, Tabarrini et al. did extensive research on 6-desfluoroquinolones showing marked anti-HIV activity in acutely, chronically, and latently HIV-1 infected cell cultures.\textsuperscript{[84]} Further optimisation of 6-desfluoroquinolones demonstrated that the bioisosteric replacement of the quinolone (47) nucleus by an 1,8-naphthyridone (48) is beneficial when a suitable arrangement of the functional groups is present at the C-6, N-1, and C-7 positions. The SAR results showed that a substitution with 1-(1,3-benzothiazol-2-yl)piperazine present at the C-7 position was advantageous.\textsuperscript{[85–87]}

### Anti-influenza agents

Human influenza also known as ‘flu’ is mainly caused by influenza A or B virus infections. This virus consists of single-stranded RNA enveloped in a glycoprotein surface, along with haemagglutinin and neuraminidase (NA). Infections with influenza A viruses of the subtypes H1N1 and H3N2 are the main causes of respiratory tract disease. Current antiviral drugs target the M2 ion-channel protein (e.g. adamantanes) and NA (e.g. zanamivir and oseltamivir). However, many resistant influenza virus strains have been reported in several countries, highlighting the need for new antiviral drugs.\textsuperscript{[88]} The first report on benzothiazole derivatives as anti-influenza came in 1969 from Paget et al. They reported the structure naphthothiazolylureas (49) effective against the coxsackievirus A21 Coe virus.\textsuperscript{[89]} Encouraged by this, Akerfeldt at KABI group, Sweden performed the in vivo preclinical screenings of aminobenzothiazoles...
(ABT) on mice infected with influenza A2 strains. A 4-chloro substituted ABT (50) (LD$_{50}$ 180 mg/kg) showed 100% animal survival against the Influenza A2 virus (Figure 17).[90]

**IRF3 agonists**

The RIG-I-like receptors (RLRs) are pathogen recognition receptors which play a major role in the pathogen sensing of RNA virus infections to initiate antiviral immunity.[91] Following the AViiD HTS platform against a very large library of 47,000 small compounds, a benzobisthiazole hit compound KIN1000 (51) was identified as an RLR signal activating agent. This HTS procedure utilised the Huh7 reporter cell lines containing the ISG54, ISG56, or IFN-$

promoters, all IRF3-genes triggered through the RLR pathway. Finally, a new lead analogue KIN1148 (52), was designed by structural modifications of the phenyl with naphthyl ring. Compound KIN1148 showed increased protection and reduced viral load when administered along with suboptimal dose of H1N1 vaccine to influenza virus A-infected mice. KIN1148 also induced an influenza virus-specific IL-10 and Th2 response by T cells in the lymph nodes (Figure 18).[92]

**AKT Inhibitors**

The protein kinase-B (AKT) pathway is an important mechanism in the infection and replication of influenza viruses. Inhibition of AKT kinase activity has been reported...
to suppresses the entry and replication of influenza virus.\cite{93} To probe its significance, Peterson et al. at the University of Kansas, USA, focused on the discovery of novel antiviral agents targeting the AKT-IV. They identified a potent benzothiazolyl AKT-IV inhibitor (ChemBridge 5233705) (53), having broad-spectrum antiviral and anti-cancer activity. SAR showed that the replacement of the N-ethyl substituent with N-hexyl (54) and N-dodecyl (55) groups increased the antiviral potencies of AKT-IV inhibitors against the recombinant parainfluenza virus 5 (PIV5), expressing luciferase in HeLa cells.\cite{94} Further, detailed biomolecular studies revealed that the cationic benzimidazole moiety exhibited dose dependent paradoxical positive or negative effects on the phosphorylation of AKT. Moreover, compound 53 was found to trigger swelling, disintegration and depolarisation of mitochondria, elevation of ROS, and essentially, the complete inhibition of the cellular consumption of oxygen (Figure 19).\cite{95}

**Neuramidase inhibitors**

Galochkina et al. reported that a novel tricyclic structure containing 2-substituted 7,8-dihydro-6H-imidazo[2,1-b][1,3]benzothiazol-5-ones (56) was a promising anti-influenza A virus. The thiophene substituted derivative demonstrated excellent antiviral activity (CC$_{50} > 1000$ µM, SI = 77). To get insight into the molecular mechanism of its anti-influenza potential, a detailed NA enzyme inhibition assay was also carried out; however, the result was not significant (Figure 20).\cite{96}

**Bcl-2 inhibitors**

Apoptosis is a host cellular defence mechanism against virus infections generally initiated by the pattern recognition receptors (PRRs). These receptors recognise the attacking viruses and signal to Bcl-2 proteins which leads to mitochondria membrane permeabilisation (MoMP),
cytochrome c release and ultimately cell death (Shim, et al. [97]). Bulanova et al. identified some safer benzothiazole derivatives (57, 58 & 59) as inhibiting cellular anti-apoptotic Bcl-2 proteins (Bcl-2i), which induced the premature cell deaths of RNA/DNA virus infected cells. The apoptosis assay was performed on the viability and death of influenza A virus infected cells (Figure 21). [98]

**Anti-West Nile virus**

West Nile virus (WNV) is a single-stranded RNA flavivirus typically spread by mosquitoes. Currently, no drug or vaccine is available for the treatment of WNV. Similar to the other flaviviruses, WNV NS2BNS3 protease is also a promising target for WNV treatment. [99] Using robust screening procedures, including *in silico*, HTS, *in vitro* and *in vivo* assessments, on a large array of compounds through hit-to-lead (H2L) optimisation has resulted in many potent WNV PIs. Scientists at Georgetown University Medical Center, USA, also performed an HTS assay for the WNV protease by assessing approximately 32 000 small molecules. Interestingly, they discovered an 8-hydroxyquinoline (8-HQ) chemotype analogous with compound 60 as a promising PI (Mueller, et al. [100]). Further insight into the SAR of 8-HQ was also established by making substitutions...
around the core template. Replacement of thiazole (60) with a benzothiazole (61) moiety at the R3 position provided the analogues with great inhibitory activity that formed strong interactions with the WNV NS2B/NS3pro residues Asp75 at the active site.[101] Likewise, NUS-Singapore researchers implemented a preliminary screening of approximately 110 compounds for the WNV NS2BNS3 protease inhibition assay at 100 µM and identified a benzothiazolacetamide derivative (62) as a WNV PI. This hit molecule underwent more extensive optimisation in a subsequent step to yield a potent lead compound (63) containing an ethyl group at the para position of the phenyl ring. The affinity of the lead was found to improve by several orders of magnitude against WNV NS2B NS3 protease than DENV2 NS2B NS3 protease (Figure 22).[102]

Discussion

Benzothiazole ring has gained much attention because of its easy functionalisation at various ring positions, which makes them attractive synthetic compounds for designing and development of the novel antiviral drugs in future. Various benzothiazole analogues were reported to have promising antiviral properties. We summarised their antiviral potential along with their molecular frameworks in Table 1. Many of these compounds had desired pharmacokinetic properties and broad spectrum of antiviral activity against the wide range of viruses acting through different molecular targets such as protease, helicase, polymerase, reverse transcriptase, integrase and neuramidase.

Ongoing research shows that aminobenzothiazoles (ABTs) are a very promising and common pharmacophore for the design and development of inhibitors/agonists against the NS2B/NS3 protease, RNA helicase, Bcl-2i, IRF3 and reverse transcriptase. ABT containing 8-hydroxyquinoline (8-HQ) compounds (1) exhibited very promising antiviral activity by DENV2 NS2B-NS3 protease inhibition. These inhibitors bind into the active site of the NS3pro near to the catalytic triad residues: His51, Asp75 and Ser135 like the peptide-based inhibitors. The observed

![Figure 22](https://wileyonlinelibrary.com)
| Chemical classes                              | Pharmacophore | Mechanisms of action                      | Viruses         | Clinical status         |
|----------------------------------------------|---------------|-------------------------------------------|-----------------|-------------------------|
| 8-Hydroxyquinoline analogue of benzothiazole| ![Structure]  | NS2B/NS3 protease inhibitor               | DENV2 & WNV     | NA                      |
| Benzoisothiazolyl carboxamide                | ![Structure]  | RNA helicase inhibitor                    | DENV & Influenza A | NA                      |
| Pyridobenzothiazole                          | ![Structure]  | RNA polymerase (RdRp) inhibitor           | DENV2           | NA                      |
| Benzoisothiazolyl oligomers (Dyes)           | ![Structure]  | NS3 helicase inhibitors                   | HCV             | NA                      |
| Benzoisothiazolyl carbanucleoside            | ![Structure]  | NS5B polymerase inhibitors               | HCV             | NA                      |
| Disulphonamide analogue of benzothiazole     | ![Structure]  | HCV replicon inhibitors                   | HCV             | NA                      |
| Benzoisothiazolyl urea                       | ![Structure]  | –                                         | HSV & Influenza | Immunosuppressive drug  |
| Benzoisothiazolyl-dihydropyridine-3-carboxamide | ![Structure] | Reverse transcriptase Inhibitors           | HIV             | NA                      |
| Bis-Tetrahydrofuranyl-urethane analogue of benzothiazole | ![Structure] | Protease Inhibitor                        | HIV & COVID-19  | Phase I & IIa-completed (HIV)[104]  |
|                                               |               |                                           |                 | Phase 3-ongoing (COVID-19)[105]     |
|                                               |               |                                           |                 | (Janssen R&D Ireland)            |
potency of compounds could be attributed due to the favourable hydrophobic interactions of lipophilic benzothiazole and 8-HQ moieties at S2 and S1 hydrophobic pockets, respectively. Another ABT derivative containing pyrimidine nucleus (4) strongly inhibited DENV NS3 helicase. The amino group of compound 4 formed a hydrogen bond with Arg599 at the active site. Docking analysis of 6-methyl-N-(4-nitrophenyl)benzothiazol-2-amine (24) at the active site of HCV RdRp protein structure showed that it occupied the thumb domain of the enzyme and made close contacts with the surrounding residues, Leu419, Leu497, Arg501 and Trp528. It is thus observed that, in general, ABT analogues could interact strongly with varied molecular targets of different viruses and these ligands have broad-spectrum structural features that make them proficient for inhibiting numerous significant target proteins.

Figure 23 reveals a common structural features ABTs where the lipophilic benzothiazole moiety is linked to the terminal aryl/heteroaryl nucleus through amino/amide linkage as hydrogen bonding domain.

In addition, bis-THF analogue containing ABTs (34) have proved to be effective HIV-1 PIs. Bis-THF analogues with HIV-1 protease shows extensive interactions at the active site. The pharmacophore model suggests the hydrophobic, electrostatic and hydrogen bonding with the backbone atoms located in the S2 to S2’-subsites whereas the hydroxyl group binds to a catalytic aspartate while a P1 and P1’ ligand occupy the S1 and S1’ subsites (Fig 12). Using the X-ray crystallography, the bis-THF template was further optimised and developed into the first clinical candidate ABT derivative TMC310911 (ASC09, 64) with improved resistance profile and higher genetic barrier to resistance. TMC310911 has completed phase I and phase IIa clinical trials and the drug was reported to be safe and well tolerated. TMC310911 formed hydrogen bond networks with the ASP25, ASP25 δ, ASP29, ASP30, ASP30 δ and GLY27 residues.103

**Conclusion, authors comments and future perspective**

Despite some progress in recent years, the fight against antiviral diseases remains a great challenge. Antiviral drug discovery has seen huge leaps in scientific research and
Benzothiazoles as antiviral agents

technological innovations. During the past few years, significant advancements have been made in understanding the molecular targets of viral proteins and based on these many biochemical assays have been developed. In silico screening, robust in vitro HTS and in vivo models have become increasingly important tools for the discovery of antiviral leads. Several antiviral compounds containing a benzothiazole scaffold have emerged as excellent leads in HTS viral enzyme assay and subgenomic replicon cells assay. After an overview of the antiviral benzothiazole analogues, it was noticed that there is a general trend of designing molecules with simple substitutions at the C-2 position with amide or aryl ring. Some of these compounds were unusually effective against a broad spectrum of viruses, as their target genome shares a common homology. This clearly indicates that there is still room for improvement in terms of efficacy, toxicity and physicochemical properties.

Moreover, the ongoing pandemic of COVID-19 is defining global health crisis of our time and underscores the urgency to develop effective vaccine or medicine against this virus. In this regards, hundreds of reports have been published uncovering the whole genome sequence of SARS-CoV-2 variants. Experts around the world have been gearing up to repurpose existing drugs especially antiviral drugs against the coronavirus. One PI, benzothiazolyl analogue ASC09F (64), is currently under evaluation in clinical trials as combinational therapy to assess the efficacy of ASC09F and ritonavir for 2019-nCoV pneumonia.

No doubt, significant advancement in the discovery of novel benzothiazolyl antiviral agents has been made, and there is a plethora of preclinical candidates. There are still lots of benzothiazoles having drug like properties with varied biological activities have not been investigated for their antiviral potential. Putting drug repurposing of these large-scale data will play a principal role in clinical development of novel antiviral drugs in the future. Various computational approaches along with HTS can be used to design novel antiviral agents not only effective against COVID-19 but against any deadly viruses.

**Declarations**

**Conflict of interest**

Authors have no conflicts of interest.

**Acknowledgements**

The authors would like to express their gratitude to King Khalid University, Abha, Saudi Arabia for providing administrative and technical support.

**References**

1. Cavicchioli R et al. Scientists’ warning to humanity: microorganisms and climate change. Nat Rev Microbiol 2019; 17: 569–586.
2. Jonas O, Seifman R. Do we need a Global Virome Project? The Lancet 2019; 7: 1314–1316.
3. Carroll D et al. Building a global atlas of zoonotic viruses. Bull World Health Organ 2018; 96: 292–294.
4. Ilori EA et al. Increase in Lassa fever cases in Nigeria, January–March 2018. Emerg Infect Dis 2019; 25: 1026–1027.
5. Patralekha C. Nipah virus outbreak in India. Lancet 2018; 391: 2200.
6. Goldani LZ. Yellow fever outbreak in Brazil, 2017. Braz J Infect Dis 2017; 21: 123–124.
7. Malvy PD et al. Ebola virus disease. Lancet 2019; 393: 936–948.
8. Agumadu VC, Ramphul K. Zika virus: a review of literature. Cureus 2018; 10: 3025.
9. Mitjà O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. Lancet Global Health 2020; 8: e639–e640.
10. Gelderblom HR. Structure and classification of viruses. In: Baron S, ed. The Medical Microbiology, 4th edn. Galveston, TX: University of Texas Medical Branch at Galveston, 1996. Chapter 41. https://www.ncbi.nlm.nih.gov/books/NBK8174/.
11. Howard CR, Fletcher NF. Emerging virus diseases: can we ever expect the unexpected? Emerg Microbes Infect 2012; 1: 46.
12. Dilnessa T, Zeleke H. Cell culture, cytopathic effect and immunofluorescence diagnosis of viral infection. J Microb Mod Tech 2017; 2: 1–8.
13. Gao Q et al. A cell-based high-throughput approach to identify inhibitors of influenza A virus. Acta Pharm Sin B 2014; 4: 301–306.
14. Chaudhuri S et al. Innovation and trends in the development and approval of antiviral medicines: 1987–2017 and beyond. Antivir Res 2018; 155: 76–88.
15. Leung DT, Sacks SL. Docosanol: a topical antiviral for herpes labialis. Expert Opin Pharmacother 2004; 5: 2567–2571.
16. Patel MC et al. Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol 2014; 9: 811–829.
17. Cuny GD et al. Inosine-5’-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002–2016). Exp Opin Ther Pat 2017; 27: 677–690.
18. Barmania F, Pepper MS. C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection. Appl Transl Genom 2013; 2: 3–16.
19. Blair W, Cox C. Current landscape of antiviral drug discovery. F1000Res 2016; 5: 202.
20. Schinazi RF et al. Handb Exp Pharmacol. Verlag Berlin Heidelberg: Springer; 2009; 25–51.
Benzothiazoles as antiviral agents

21. Hassan MZ et al. Therapeutic potential of coumarins as antiviral agents. *Ear J Med Chem* 2016; 123: 236–255.

22. Murgueitio MS et al. In silico virtual screening approaches for anti-viral drug discovery. *Drug Discov Today Technol* 2012; 9: 219–225.

23. Osman H et al. 3,5-Bis(arylidene)-4-piperidones as potential dengue protease inhibitors. *Acta Pharm Sin B* 2017; 7: 479–484.

24. Murray NE et al. Epidemiology of dengue: past, present and future prospects. *Clin Epidemiol* 2013; 5: 299–309.

25. Low JGH et al. Current status of dengue therapeutics research and development. *J Infect Dis* 2017; 215: S96–S102.

26. Lai H et al. Characterization of 8-hydroxyquinoline derivatives containing aminobenzothiazole as inhibitors of dengue virus type 2 protease in vitro. *Antivir Res* 2013; 97: 74–80.

27. Wu H et al. Novel dengue virus NS2B/NS3 protease inhibitors. *Antimicrob Agents Chemother* 2015; 59: 1100–1109.

28. Xu T et al. Structure of the dengue virus helicase/nucleoside triphosphatase catalytic domain at a resolution of 2.4 Å. *J Virol* 2005; 79: 10278–10288.

29. Sweeney NL et al. Benzothiazole and pyrrolone flavivirus inhibitors targeting the viral helicase. *ACS Infect Dis* 2015; 1: 140–148.

30. Halim SA et al. Targeting dengue virus NS-3 helicase by ligand based pharmacophore modeling and structure based virtual screening. *Front Chem* 2017; 5: 88.

31. Tarantino D et al. Targeting flavivirus RNA dependent RNA polymerase through a pyridobenzothiazole inhibitor. *Antivir Res* 2016; 134: 226–235.

32. Cannalire R et al. Broad spectrum anti-flavivirus pyridobenzothiazolones leading to less infective viruses. *Antivir Res* 2019; 167: 6–12.

33. Shahnazarian V et al. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. *Ann Gastroenterol* 2018; 31(5): 541–551.

34. Lavanchy D. The global burden of hepatitis C. *Liver Int* 2009; 29: 74–81.

35. De Clercq E. The design of drugs for HIV and HCV. *Nat Rev Drug Discov* 2007; 6: 1001–1018.

36. Smolders EJ et al. Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and/or renal impairment. *Drug Saf* 2016; 39: 589–611.

37. Raney KD et al. Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target. *J Biol Chem* 2010; 285: 22725–22731.

38. Paramasurupia DA. Delicate dance in treating hepatitis C infections and overcoming resistance. In Gupta SP eds. *The Viral Proteases and Their Inhibitors*, 1st edn. Cambridge, Massachusetts, United States: Academic Press, 2017.

39. Li K et al. Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline. *J Med Chem* 2012; 55: 3319–3330.

40. Wei Y et al. Discovery of novel hepatitis C Virus NS5B polymerase inhibitors by combining random forest, multiple e-pharmacophore modeling and docking. *PLoS One* 2016; 11: e0148181.

41. Manfroni G et al. Pyridobenzothiazole derivatives as new chemotype targeting the HCV NS5B polymerase. *Bioorg Med Chem* 2012; 20: 866–876.

42. Kwong CD et al. Novel substituted pyrimidines as HCV replication (replicase) inhibitors. *Bioorg Med Chem Lett* 2012; 22: 1160–1164.

43. Arasappan A et al. 5-Benzothiazole substituted pyrimidine derivatives as HCV replication (replicase) inhibitors. *Bioorg Med Chem Lett* 2012; 22: 3229–3234.

44. Girijavallabhan VM et al. Synthesis and SAR of pyridothiazole substituted pyrimidine derived HCV replication inhibitors. *Bioorg Med Chem Lett* 2012; 22: 5652–5657.

45. Blight KJ, Norgard EA. HCV Replicon Systems. In Tan SL eds. *The Hepatitis C VIRUSES: Genomes and Molecular Biology*, Horizon Bioscience: Norfolk (UK), 2006.

46. Liu N et al. The discovery and characterization of a novel scaffold as a potent hepatitis C virus inhibitor. *Chem Commun* 2016; 52: 3340–3343.

47. Montalvão S et al. Synthesis and biological evaluation of 2-aminobenzothiazole and benzimidazole analogs based on the clathrodin structure. *Arch Pharm Chem Life Sci* 2016; 349: 137–149.

48. Neys J et al. Structure-Activity Relationship of new anti-hepatitis C virus agents: heterobicycle–coumarin conjugates. *J Med Chem* 2009; 52: 1486–1490.

49. Peng HK et al. Anti-hepatitis C virus RdRp activity and replication of novel anilinobenzothiazole derivatives. *Antivir Res* 2013; 100: 269–275.

50. De Clercq E. Selective anti-hepatitis C virus agents. *Antivir Chem Chemother* 2013; 23: 93–101.

51. El-Sherbiny MA. Synthesis of certain pyrimido[2,1-b]benzothiazole and benzothiazolo[2,3-b]quinazoline derivatives for in vitro antitumor and antiviral activities. *Arzneimittelforschung* 2000; 50: 848–853.

52. Abdel-Aziza HA et al. Stereoselective synthesis and antiviral activity of (1E,2Z,3E)-1-(piperidin-1-yl)-1-(aryl-hydrazono)-2-[(benzoyl/benzothiazol-2-oyl)hydrazono]-4-(aryl(1))but-3-enes. *Arch Pharm* 2010; 343: 152–159.

53. Scheetz ME et al. Frentizole, a novel immunosuppressive, and azathio- prisine: their comparative effects on host resistance to Pseudomonas aeruginosa, Candida albicans, Herpes Simplex virus, and influenza (Ann Arbor) virus. *Infect Immun* 1977; 15: 145–148.

54. Zhan P et al. Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. *J Med Chem* 2016; 59: 2849–2878.

55. Flexner C. HIV drug development: the next 25 years. *Nat Rev Drug Discov* 2007; 6: 959–966.

56. Maartens G et al. HIV infection: epidemiology, pathogenesis, treatment, and prevention. *Lancet* 2014; 384: 258–271.

57. Ursu O et al. Novel drug targets in 2018. *Nat Rev Drug Dis* 2019; 18: 328.
58. Castro HC et al. HIV-1 reverse transcriptase: a therapeutical target in the spotlight. *Curr Med Chem* 2006; 13: 313–324.

59. Akbay A et al. Synthesis and HIV-1 reverse transcriptase inhibitor activity of some 2, 5, 6-substituted benzoxazole, benzimidazole, benzothiazole and oxazolo (4, 5-b) pyridine derivatives. *Arzneim Forsch Drug Res* 2003; 53: 266–271.

60. Cheung PK et al. A parallel synthesis approach to the identification of novel diheteroarylamide-based compounds blocking HIV replication: potential inhibitors of HIV-1 pre-mRNA alternative splicing. *J Med Chem* 2016; 59: 1869–1879.

61. Shkreta LM et al. Modulation of the splicing regulatory function of ssrsf10 by a novel compound that impairs HIV-1 replication. *Nucleic Acids Res* 2017; 45: 4051–4067.

62. Ghosh AK. Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. *J Med Chem* 2016; 59: 5172–5208.

63. Mitsuya H et al. Development of protease inhibitors and the fight with drug-resistant HIV-1 variants. In Jeang KT eds. HIV-1: Molecular biology and pathogenesis: clinical application. Cambridge, Massachusetts, United States: Academic Press; 2007: 169–197.

64. Renukuntla J. Approaches for enhancing oral bioavailability of peptides and proteins. *Int J Pharm* 2013; 447: 75–93.

65. Ghosh AK et al. Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. *Bioorg Med Chem* 2007; 15: 7576–7580.

66. Ghosh AK et al. Design and development of highly potent hiv-1 protease inhibitors with a crown-like oxotricyclic core as the P2-ligand to combat multidrug-resistant HIV variants. *J Med Chem* 2017; 60: 4267–4278.

67. Ghosh AK et al. Design and synthesis of highly potent HIV-1 protease inhibitors containing tricyclic fused ring systems as novel P2 ligands: structure-activity studies, biological and x-ray structural analysis. *J Med Chem* 2018; 61: 4561–4577.

68. Surleraux DL et al. Design of HIV-1 protease inhibitors active on multidrug-resistant virus. *J Med Chem* 2005; 48: 1965–1973.

69. Koh Y et al. In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors. *J Vir* 2010; 84: 11961–11969.

70. Takamatsu Y et al. Novel protease inhibitors containing c-5-modified bis-trihydroxofuranylurethane and aminobenzothiazole as P2 and P2’ ligands that exert potent antiviral activity against highly multidrug-resistant HIV-1 with a high genetic barrier against the emergence of drug resistance. *Antimicrob Agents Chemother* 2019; 63: 00372-19.

71. Ali A et al. Structure-based design, synthesis and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones. *J Med Chem* 2010; 53: 7699–7708.

72. Jonckers TH et al. Benzoazolone and benzothiazole amidines as novel pharmacokinetic enhancers of HIV protease inhibitors. *Bioorg Med Chem Lett* 2012; 22: 4998–5002.

73. Ung PM et al. An allosteric modulator of HIV-1 protease shows equipotent inhibition of wild-type and drug-resistant proteases. *J Med Chem* 2014; 57: 6468–6478.

74. Pommier Y et al. Integrate inhibitors to treat HIV/AIDS. *Nat Rev Drug Discov* 2005; 4: 236–248.

75. Wong E et al. HIV pharmacotherapy: a review of integrate inhibitors. *J Am Acad PAs* 2016; 29: 36–40.

76. Gu WG et al. Discovery of a novel HIV-1 integrase inhibitor from natural compounds through structure based virtual screening and cell imaging. *FEBS Lett* 2014; 588: 3461–3468.

77. Amir M et al. Synthesis and antiviral activity of pyrazolinone and pyrazole analogues containing quinoline moiety. *Ind J Chem* 2013; 52B: 1493–1499.

78. Vicini P et al. Synthesis and biological evaluation of benzo[d]isothiazole, benzothiazole and thiazole Schiff bases. *Bioorg Med Chem* 2003; 11: 4785–4789.

79. Bhavsar D et al. Synthesis and in vitro anti-HIV activity of N-1,3-benzo[d]thiazol-2-yl-2-(2-oxo-2H-chromen-4-yl)acetamide derivatives using MTT method. *Bioorg Med Chem Lett* 2011; 21: 3443–3446.

80. Shaikh FM et al. Synthesis of some new 2-amino-6-thiocyanato benzothiazole derivatives bearing 2,4-thiazolidinediones and screening of their in vitro antimicrobial, antitubercular and antiviral activities. *Med Chem Res* 2015; 24: 3129–3142.

81. Heredia A et al. A novel small-molecule inhibitor of HIV-1 entry. *Drug Des Devel Ther* 2015; 9: 5469–5478.

82. Urano E et al. Novel postentry inhibitor of human immunodeficiency virus type 1 replication screened by yeast membrane-associated two-hybrid system. *Antimicrob Agents Chemother* 2011; 55: 4251–4260.

83. Kamo M et al. Synthesis of the biotinylated anti-HIV compound BMMP and the target identification study. *Bioorg Med Chem Lett* 2016; 26: 43–45.

84. Tabarrini O et al. Structure-activity relationship study on anti-HIV 6-desfluoroquinolones. *J Med Chem* 2008; 51: 5454–5458.

85. Massari S et al. 1,8-naphthyridine derivative targets the hiv-1 tat-mediated transcription and potently inhibits the HIV-1 replication. *J Med Chem* 2010; 53: 641–648.

86. Tabarrini O et al. 6-desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors. 6-desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors. *Fat Med Chem* 2010; 2: 1161–1180.

87. Natalini B et al. Synthesis and chromatographic enantioreolution of anti-HIV quinolone derivatives. *Talanta* 2011; 85: 1392–1397.

88. Das K et al. Structures of influenza A proteins and insights into antiviral
drug targets. *Nat Struct Mol Biol* 2010; 17: 530–538.
89. Charles J et al. Heterocyclic substituted ureas. II. Immunosuppressive and antiviral activity of benzothiazole- and benzoxazoleureas. *J Med Chem* 1969; 12: 1016–1018.
90. Akerfeldt S. Studies on the in vivo antiviral effects of benzothiazole derivatives against various influenza A2 strains. *J Med Chem* 1970; 13: 1012–1013.
91. Loo YM, Gale M Jr. Immune signaling by RIG-I-like receptors. *Immunity* 2011; 34: 680–692.
92. Probst P et al. A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response. *Vaccine* 2017; 35: 1964–1971.
93. Hirata N et al. Inhibition of Akt kinase activity suppresses entry and replication of influenza virus. *Biochem Biophys Res Commun* 2014; 450: 891–898.
94. Sun Q et al. Synthesis and biological evaluation of analogues of AKT (protein kinase B) inhibitor-IV. *J Med Chem* 2011; 54: 1126–1139.
95. Meinig JM, Peterson BR. Anticancer/antiviral agent Akt inhibitor-IV massively accumulates in mitochondria and potently disrupts cellular bioenergetics. *ACS Chem Biol* 2015; 10: 570–576.
96. Galochkina AV et al. Synthesis of novel derivatives of 7,8-dihydro-6H-imidazo[2,1-b][1,3]benzothiazol-5-one and their virus-inhibiting activity against influenza A virus. *Arch Pharm* 2019; 352: e1800225.
97. Shim JM. Influenza virus infection, interferon response, viral counter-response, and apoptosis. *Viruses* 2017; 9: E223.
98. Bulanova D et al. Antiviral properties of chemical inhibitors of cellular anti-apoptotic Bcl-2 proteins. *Viruses* 2017; 9: 271.
99. Chappell KJ et al. West Nile Virus NS2B/NS3 protease as an antiviral target. *Curr Med Chem* 2008; 15: 2771–2778.
100. Mueller NH et al. Identification and biochemical characterization of small-molecule inhibitors of west nile virus serine protease by a high-throughput screen. *Antimicrob Agents Chemother* 2008; 52: 3385–3393.
101. Ezgimen M et al. Characterization of the 8-hydroxyquinoline scaffold for inhibitors of West Nile virus serine protease. *Antiviral Res* 2012; 94: 18–24.
102. Samanta S et al. Synthesis and in vitro evaluation of West Nile virus protease inhibitors based on the 2-[6-[(S)-3-phenyl-4H-[1,2,4]triazol-2-ylsulfanyl]acetyl amino]benzothiazol-2-ylsulfanyl]acetamide scaffold. *Chem Med Chem* 2013; 8: 994–1001.
103. Dierynck I et al. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors. *Antimicrob Agents Chemother* 2011; 55: 5723–5731.
104. United States National Library of Medicine. ChemIDplus advanced: TMC310911. https://chem.nlm.nih.gov/chemidplus/rn/1000287-05-7. (accessed 29 May 2020).
105. https://clinicaltrials.gov/ct2/show/NCT04261270. (accessed 29 May 2020).